India and South Africa recently urged the World Trade Organization to suspend intellectual property protections for COVID-19 vaccines and treatments. The claim is that this would allow developing countries to manufacture “cheap” COVID-19 therapeutics and vaccines, hastening the end to the pandemic—at least, that’s what proponents claim. They’re wrong. Dangerously wrong. Gutting IP protections won’t make COVID-19 medications more readily available but it will set a terrible precedent that will chill future medical innovation.
Recent Posts
- Strong IP Protections are the Key to Growing U.S. Manufacturing
- The PTAB’s Most Cited Case Law for Ex Parte Appeal Reversals Should Be in Your Appeal Briefs
- Other Barks & Bites for Friday, March 28: House Passes Interagency R&D Bills; CAFC Affirms Induced Infringement Finding Against Mylan; and Several Drug Patent Bills Introduced into Congress
- Closing the PTAB Loophole: Targeting Real Threats to U.S. Innovation Without Overreaching
- A Teapot Steeped with Dicta: An Update on In re Maatita and Design Definiteness